Back to the fridge
Curious science

Bee venom vs. tumors

Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer

Duffy C et al. · npj Precision Oncology · 2020

The big question

People have used honeybee products such as honey and venom as medicine for thousands of years. Researchers wanted to know whether honeybee venom can fight hard-to-treat breast cancers, such as triple-negative and HER2-enriched types, and how it might work.

What they did

The team tested honeybee venom and melittin, its main ingredient, on breast cancer cells and normal cells grown in the lab. They studied how melittin attacks the outer layer of cancer cells and built a modified version designed to target cancer cells better. They also tested melittin with the chemotherapy drug docetaxel in mice.

What they found

Venom and melittin killed triple-negative and HER2-enriched breast cancer cells most strongly. Normal skin cells needed about four times as much venom to be harmed (22.17 compared with about 5.6 to 5.8 units for two cancer cell types). Within 10 to 60 minutes, the outer layer of cancer cells began breaking down. Melittin also blocked growth signals from two proteins, EGFR and HER2, that help these cancers grow. In mice, melittin made docetaxel better at slowing tumor growth.

Why it matters

This study explains how a natural substance can single out aggressive breast cancer cells. That knowledge could help scientists design new treatments.

What it doesn't mean

This work was done in lab dishes and mice, not people. It does not mean bee stings or venom products can treat cancer; please do not try them.

Read the original abstract
Despite decades of study, the molecular mechanisms and selectivity of the biomolecular components of honeybee (Apis mellifera) venom as anticancer agents remain largely unknown. Here, we demonstrate that honeybee venom and its major component melittin potently induce cell death, particularly in the aggressive triple-negative and HER2-enriched breast cancer subtypes. Honeybee venom and melittin suppress the activation of EGFR and HER2 by interfering with the phosphorylation of these receptors in the plasma membrane of breast carcinoma cells. Mutational studies reveal that a positively charged C-terminal melittin sequence mediates plasma membrane interaction and anticancer activity. Engineering of an RGD motif further enhances targeting of melittin to malignant cells with minimal toxicity to normal cells. Lastly, administration of melittin enhances the effect of docetaxel in suppressing breast tumor growth in an allograft model. Our work unveils a molecular mechanism underpinning the anticancer selectivity of melittin, and outlines treatment strategies to target aggressive breast cancers.

Abstract reproduced from Duffy C et al., npj Precision Oncology (2020), under a CC BY 4.0 license. Plain-English summary by Womanhattan.

This summary was written with AI assistance and checked against the original paper. It is for learning, not medical advice. Talk with your care team before changing anything about your health or treatment.